Related Experiment Video
Updated: Jun 11, 2026
06:55
Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
[Health services research in oncology using claims data]
1Abteilung Gesundheitsökonomie, Gesundheitspolitik und Versorgungsforschung, ZeS, Universität Bremen, Bremen, Germany. hoffmann@zes.uni-bremen.de
Medizinische Klinik (Munich, Germany : 1983)
|June 29, 2010
Summary
Oncologists prescribe significantly more compounded drugs than other physicians, at a much higher cost. This highlights a critical need for health services research in oncology using insurance claims data.
Area of Science:
- Oncology
- Health Services Research
- Pharmacoepidemiology
Context:
- Cancer care is a growing public health concern with increasing treatment costs.
- Limited understanding exists regarding the healthcare utilization patterns of cancer patients.
- German statutory health insurance funds provide valuable claims data for research.
Purpose:
- To analyze drug prescription patterns among oncologists using health insurance claims data.
- To compare the utilization and cost of compounded prescriptions by oncologists versus other physicians.
- To assess the utility of claims data for health services research in oncology.
Summary:
- Analysis of 1.98 million prescriptions from German statutory health insurance (GEK) data (Oct-Dec 2008).
- Oncologists had a 17-fold higher rate of compounded prescriptions (34.4%) compared to other physicians (2.0%).
- Compounded prescriptions by oncologists were substantially more expensive (median €397.68 vs. €15.45).
Impact:
- Reveals significant differences in prescribing practices and costs between oncologists and other physicians.
- Underscores the urgent need for health services research in oncology.
- Demonstrates the potential of linked insurance claims data for understanding cancer patient care, with limitations for specific drug details.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...